NasdaqGS:HUMABiotechs
Humacyte (HUMA) Valuation in Focus After Encouraging Ukraine Trauma Results and New Patent Milestone
Humacyte (HUMA) has caught attention after Military Medicine published results from its humanitarian program in Ukraine. The publication highlights Symvess’s continued high patency, 100% limb salvage, and no conduit infections in trauma cases.
See our latest analysis for Humacyte.
In addition to the strong clinical data from Ukraine, Humacyte recently secured an important U.S. patent for its bioengineered esophagus, expanding the company’s portfolio of protected regenerative medicine...